RHHBY's higher dose of multiple sclerosis drug Ocrevus did not meet its primary goal when compared to the approved 600 mg dose in relapsing multiple sclerosis patients.

Regeneron and Bayer's efforts to defend their lucrative eye disease therapy Eylea from competition have been boosted by FDA approval of a new high-dose formulation of the drug. The US regulator ...

The trial design is similar to the most recent Phase 3 trial in wet AMD that lead to the approval of EYLEA high dose and VABYSMO. The design applies the redosing criteria generally utilized in ...

The Eylea franchise -- including a high-dose (HD) formulation that first earned approval in 2023 -- is facing stiff competition, biosimilar and otherwise. The medicine's sales growth has slowed ...

Two one-shot doses of 4D-150 are being tested in the study and compared to Eylea. The high dose of the gene therapy – which is designed to express both aflibercept and an RNA interference (RNAi ...

Alvotech leads in developing EYLEA high dose and Entyvio biosimilars. - Symphony biosimilar approval is expected by year-end, with global reach in early 2025. - Exclusion of HUMIRA from ...

Pipeline Expansion: - Investments in early-stage pipeline include over 15 molecules in development. - Alvotech leads in developing EYLEA high dose and Entyvio biosimilars. - Symphony biosimilar ...

Bayer's AI Innovation Platform (AIIP), powered by Google Cloud technology, streamlines the development of AI-driven medical ...

An add-on agent designed to boost drugs that treat age-related macular degeneration failed to show any benefit in two phase 3 ...